Medium- and Macro-Cyclic Benzyl Heterocycles as OX2R Agonists
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for narcolepsy and other disorders associated with orexin insufficiency, such as excessive daytime sleepiness and cataplexy, are symptomatic and lack a cure, necessitating the development of pharmacotherapeutics to restore lost orexin signaling.
Innovation Solution
Development of small molecule, potent orexin-2 receptor (OX2R) agonists with improved physicochemical, pharmacological, and pharmaceutical properties, designed to modulate orexin-2 receptor activity and restore orexin neurotransmission.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current symptomatic treatments are used for narcolepsy, then patient symptoms can be managed, but the root cause of orexin neuron loss cannot be cured
Solution Approach 1:
The patent uses orexin-2 receptor agonists as intermediary substances that mimic the function of lost orexin neuropeptides. These small molecule compounds bind to and activate OX2R receptors in the brain, restoring orexin signaling pathways without requiring replacement of the actual neurons. This mediator approach bridges the gap between symptom management and addressing the root cause by pharmacologically compensating for neuronal loss.
Solution Approach 2:
The invention changes the pharmacological parameters of orexin receptor activation through structurally optimized small molecule agonists. By modifying molecular structure, lipophilicity, and binding affinity parameters, the compounds achieve improved blood-brain barrier penetration and receptor selectivity, transforming the therapeutic profile from purely symptomatic to potentially disease-modifying treatment.
2Adaptability or versatility
If orexin receptor agonists are developed to restore orexin signaling, then curative potential is improved, but development complexity and time increase
Solution Approach 1:
The drug development process is segmented into distinct optimization phases: initial hit identification, lead optimization for selectivity, pharmacokinetic profile optimization, and preclinical validation. This segmentation allows systematic progression from simple orexin agonist concepts to complex, optimized small molecules with specific molecular weight ranges, lipophilicity values, and binding affinities required for central nervous system penetration and efficacy.
Solution Approach 2:
The patent develops multi-functional small molecule compounds that simultaneously achieve: (1) high affinity binding to OX2R receptors, (2) adequate blood-brain barrier penetration, (3) appropriate pharmacokinetic properties for once-daily dosing, and (4) selective activation of orexin-2 over orexin-1 receptors. This multi-functionality consolidates multiple development requirements into unified molecular design criteria.
3Ease of operation
If selective OX2R agonists are administered to increase wakefulness, then excessive daytime sleepiness is reduced, but cataplexy control may be insufficient
Solution Approach 1:
The patent achieves differential therapeutic effects through selective OX2R agonist administration that creates localized functional changes in specific brain regions. The compounds preferentially activate orexin-2 receptors in the tuberomammillary nucleus for wakefulness promotion while also engaging receptors in the dorsal raphe nucleus for cataplexy control, with each region receiving the same systemic drug but exhibiting different functional responses based on local receptor density and neural circuitry.
Data Source
AI summary
The present disclosure relates to compounds of Formula (I′):and to their prodrugs, pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein are useful for modulating orexin-2 receptor activity and may be used in the treatment of disorders in which orexin-2 receptor activity is implicated, such as narcolepsy, a hypersomnia disorder, a neurodegenerative disorder, a symptom of a rare genetic disorder, a mental health disorder, a metabolic syndrome, osteoporosis, cardiac failure, coma, or facilitating emergence from anaesthesia.